abrdn Life Sciences Investors (NYSE:HQL) Trading 0.1% Higher – Time to Buy?

Shares of abrdn Life Sciences Investors (NYSE:HQL) traded up 0.1% during trading on Monday . The company traded as high as $16.93 and last traded at $16.9170. 130,562 shares changed hands during trading, an increase of 5% from the average session volume of 124,041 shares. The stock had previously closed at $16.90.

abrdn Life Sciences Investors Price Performance

The company’s 50 day moving average is $16.96 and its 200-day moving average is $15.84.

abrdn Life Sciences Investors Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, January 12th. Shareholders of record on Friday, November 21st were paid a dividend of $0.50 per share. The ex-dividend date was Friday, November 21st. This represents a $2.00 dividend on an annualized basis and a yield of 11.8%. This is an increase from abrdn Life Sciences Investors’s previous quarterly dividend of $0.42.

Institutional Investors Weigh In On abrdn Life Sciences Investors

Institutional investors have recently made changes to their positions in the company. Geneos Wealth Management Inc. grew its holdings in shares of abrdn Life Sciences Investors by 200.1% in the second quarter. Geneos Wealth Management Inc. now owns 2,293 shares of the company’s stock worth $29,000 after acquiring an additional 1,529 shares during the period. Global Retirement Partners LLC boosted its position in abrdn Life Sciences Investors by 187.8% in the fourth quarter. Global Retirement Partners LLC now owns 7,039 shares of the company’s stock worth $118,000 after purchasing an additional 4,593 shares during the last quarter. Cornerstone Advisors LLC bought a new stake in shares of abrdn Life Sciences Investors during the 3rd quarter valued at about $175,000. Stephens Inc. AR grew its stake in shares of abrdn Life Sciences Investors by 9.8% during the 2nd quarter. Stephens Inc. AR now owns 21,231 shares of the company’s stock valued at $272,000 after purchasing an additional 1,895 shares during the period. Finally, Samalin Investment Counsel LLC increased its position in shares of abrdn Life Sciences Investors by 6.7% during the 2nd quarter. Samalin Investment Counsel LLC now owns 21,782 shares of the company’s stock valued at $279,000 after purchasing an additional 1,366 shares during the last quarter. Hedge funds and other institutional investors own 32.21% of the company’s stock.

About abrdn Life Sciences Investors

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.